baber/WOPTO huggingface dataset:
Patent NZ-534077-A (NZ)
Title: Combined chainsaw and shears pruning device with chain guard member only movable when arms closed and motor deactivated
Inventor: STONES KEVIN
IPC: A01G3/033
Filed: 2004-07-13
Abstract: A vegetation pruning device 2 comprises a pair of arms 4, 6 adapted to pivot relative to each other about an axis to adjust the angle between them, and at least one handle portion 14, 16 adapted to be gripped by a user. The device also includes a motor having a rotary output drive (not visible in this view), and an endless flexible cutting element 8 mounted to a first arm, which is driven by the rotary output drive. At least one first guard member is mounted on the first arm for restricting access to the cutting element, and at least one second guard member is mounted on the second arm. The arms are pivotable between a first position allowing access to the cutting element, and a second position in which the cutting element is substantially inaccessible, and the first guard member is moveable between a third position allowing access to the cutting element and a fourth position substantially preventing access to the cutting element, and is moveable to the third position only when the arms are in the second position and/or when the motor is deactivated.
Patent NZ-534302-A (NZ)
Title: Process and apparatus for oxidising bitumen to modify its properties
Inventor: MATTHEWS JOHN BRODIE
Filed: 2004-07-23
Abstract: An apparatus for modifying bitumen is disclosed, wherein the apparatus includes a multi-section loop tube reactor. A circulation pump (21) circulates bitumen in the reactor (10) and air is introduced at air injection point (13). Bitumen is introduced into the reactor (10) at inlet (14) by variable speed pump P1. A plurality of mixers (15) are located between the air injection point (13) and a head section (24) beyond which is an outlet (27) where modified bitumen is drawn off by variable speed pump P2. A process for modifying bitumen is also disclosed, wherein the process includes the steps of passing bitumen along a tubular path, causing the bitumen to pass through a plurality of mixers in the tubular path and injecting air into the bitumen at a point along the tubular path.
Patent NZ-536180-A (NZ)
Title: 2,6-quinolinyl and 2,6-naphthyl derivatives, processes for preparing them and their uses as VLA-4 inhibitors
Inventor: KNERR LAURENT
IPC: A61P37/06
Filed: 2003-04-15
Abstract: Disclosed are compounds of formula I, wherein: X is N or CH, R1 is cycloalkyl, aryl, heterocycle, aralkyl, heterocycle-alkyl, an oxy derivative, or a bridged carbocycle, R2 is -NR4R5, -OR4 or -C(=O)NR5R6, R3 is tetrazole, -CN, -CH2OH or -CO-R7, and the remaining substituents are defined herein. The compounds are used in the manufacture of medicaments for the treatment of VLA-4 dependent diseases.
Patent NZ-537805-A (NZ)
Title: Hose fitment for disposable food container
Inventor: CARHUFF PETER
IPC: F16L33/10
Filed: 2003-06-13
Abstract: The invention relates to a hose fitment, particularly for the connection of disposable food containers to dispensing lines of food dispenser and the like. The hose fitment of the invention is adapted to securely establish fluid connection between a hose (2) and hose retaining means (1) of a food or beverage dispensing line; the hose fitment comprising a body member (10) having a first engaging surface (41) for internally engaging a hose end (40) and a sleeve member (180) comprising a second engaging surface that externally engages around the hose end to press on the hose end against the first engaging surface in a manner effective to create a tight seal between the fitment and the hose end.
Patent NZ-538781-A (NZ)
Title: Oral formulations
Inventor: ASHRAF MUHAMMAD
IPC: A61K31/4745
Filed: 2003-09-15
Abstract: Granulated oral formulations comprising rapamycin 42-ester with 3-hydroxy-2-(hydroxymethyl)-2-methylpropionic acid (CCI-779), a water soluble polymer, a surfactant, an antioxidant from 0.001% to 3% (wt/wt) and a pH modifying agent and a process for preparing the composition.
Patent NZ-539095-A (NZ)
Title: Acetyl 2-hydroxy-1,3 diaminoalkanes
Inventor: MAILLARD MICHEL
IPC: A61K31/40
Filed: 2003-09-10
Abstract: Disclosed is a compound of formula I wherein the substituents are as defined in the specification. Also disclosed is the use of compounds of formula I for for the preparation of a medicament for treating a subject who has, or in preventing a subject from developing Alzheimer's disease (AD); preventing or delaying the onset of Alzheimer's disease; treating subjects with mild cognitive impairment (MCI); preventing or delaying the onset of Alzheimer's disease in subjects who would progress from MCI to AD; treating Down's syndrome; treating subjects who have Hereditary Cerebral Hemorrhage with Amyloidosis of the Dutch-Type; treating cerebral amyloid angiopathy and preventing its potential consequences; treating other degenerative dementias; treating dementia associated with Parkinson's disease, progressive supranuclear palsy, or cortical basal degeneration; treating diffuse Lewy body type AD; and treating frontotemporal dementias with parkinsonism (FTDP).
Patent NZ-540106-A (NZ)
Title: Pharmaceutical compositions and dosage forms for buccal and sublingual delivery of tizanidine and methods of administering tizanidine sublingually or bucally
Inventor: LERNER ITZHAK E
IPC: A61K9/28
Filed: 2003-11-03
Abstract: Disclosed is a tizanidine oral dosage form comprising 0.1% to 0.5% by weight of an anti-spasmodic amount of tizanidine, an acidulant in an amount to obtain saliva with a pH of 2 to 7 when the saliva is in direct communication with the surface of the dosage form and a pharmaceutically acceptable excipient, wherein the dosage form is adapted for administration bucally or sublingually so that the tizanidine is absorbed though the mucosa lining of the mouth and the tizanidine bioavailability AUCinf is increased by 10% or more as compared to the AUCinf of an immediate release tizanidine enteral dosage form absorbed through the gastro-intestinal track having an equivalent dose of tizanidine, and optionally the dosage form has 0.1% to 0.5% by weight of a hydrophobic polymer and optionally the dosage form has 0.1% to 0.5% by weight of a polyprotic crosslinking agent.
Patent NZ-540467-A (NZ)
Title: Method of fabricating a belt and a belt used to make bulk tissue and towel, and nonwoven articles and fabrics
Inventor: KRAMER CHARLES E
IPC: D04H1/70
Filed: 2003-07-30
Abstract: Disclosed is a method for manufacturing a belt for use in the production of bulk tissue and towel, and of nonwoven articles and fabrics, said method comprising the steps of; a) providing a base substrate for the belt; b) depositing polymeric resin material onto said base substrate in a controlled manner so as to control the x, y, z dimensions of the material deposited to create a predetermined pattern in droplets; and c) at least partially setting said polymeric resin material.
Patent NZ-541937-A (NZ)
Title: Sealed bin
Inventor: FOK HUEN
Filed: 2005-08-23
Abstract: Disclosed is a sealed bin comprising a shell with an opening on top and a lid directed towards the opening, the lid comprising a surface with a fold projecting from a transverse edge made of elastically bendable material and the shell being adapted for attachment to the surface of a fixture, the fold of the lid placed between the surface of a fixture and the shell in such a way that the lid is longitudinally flexible to allow opening and closing of the shell.
Patent NZ-544352-A (NZ)
Title: Indication of the wear level of a papermaking fabric by the use of coloured or conductive yarn components
Inventor: MARTINSSON PER
IPC: D02G3/36
Filed: 2004-06-14
Abstract: The disclosure relates to wear level indicating filaments and the fabrics made thereof. Disclosed are filaments with multiple (14, 16, 18) layers surrounding a core (12) yarn, where the core and layers are distinguishable from one another so as to indicate fabric wear. Also disclosed are conductive monofilaments used to detect fabric wear, multilayer filaments used to create a guideline on a fabric, and a conductive monofilament that also has a contrasting colour used to form a fabric guideline.
Patent NZ-544545-A (NZ)
Title: Device and method for simultaneously identifying a number of blood group antigens from a single sample
Inventor: SCHWIND PETER
IPC: G01N33/80
Filed: 2004-07-08
Abstract: Device for the simultaneous and qualitative or quantitative determination of a plurality of analytes in a liquid sample is disclosed. The device comprises: A) a membrane (2) with an application zone (5) for the application of the liquid sample, B) at least two indicator zones (6), which are able to interact with the analyte(s) and C) at least one absorption region (3) which takes up the liquid after having passed the indicator zones (6). The indicator zones (6) are located between the application zone (5) and the absorption region (3). The flow directions from the application zone (5) through the respective indicator zones (6) towards an absorption region (3), known as flow tracks, are substantially parallel and at least two different flow tracks are present.
Patent NZ-546468-A (NZ)
Title: Bracing unit of glued and fastened timbers and boards for building
Inventor: LA GROUW CORNELIS
Filed: 2006-04-10
Abstract: A bracing unit for a building includes aligned frame members 2, 3, 10 such as studs, and boards 9 attached across the frame members which are glued at 12 on their faces to the faces of the frame members, and glued at their edges 11 to each other. The boards are also attached to the frame members by fasteners 13.
Patent NZ-546599-A (NZ)
Title: Carrier search methods and apparatus
Inventor: LAROIA RAJIV
IPC: H04B1/713
Filed: 2004-10-15
Abstract: Transmitting signals, such as high power narrow band signals on a periodic basis to facilitate detection of a frequency band and/or carrier signal to be used for communication with a base station are disclosed. The detected frequency band may be a downlink frequency band. The uplink frequency band to be used can be determined from a known frequency relationship between the detected downlink carrier and a corresponding uplink carrier, or by monitoring the detected downlink frequency band for information indicating the uplink frequency band/carrier to be used. Carrier search methods involving searching for the narrowband high power signals used to provide carrier information and/or to indicate the frequency band to be monitored are also disclosed. Power detection methods can be used to detect the high power signals avoiding the need for symbol timing synchronization and/or channel estimation with regard to detection of the signals used to locate the frequency band to be used.
Patent NZ-547274-A (NZ)
Title: A recombinant protein with cancer suppression action, its encoding gene and use
Inventor: ZHU BING
IPC: C07K14/47
Filed: 2003-11-03
Abstract: Provided is a circularly permuted modified TRAIL recombinant protein having an anti-cancer effect. Also provided is the use of the protein and corresponding protein encoding nucleic acid in the production of a medicament to treat various cancers.
Patent NZ-547758-A (NZ)
Title: Cementitious pipes
Inventor: BAKER STEPHEN D
IPC: F16L9/08
Filed: 2004-11-19
Abstract: A cementitious pipe has a tubular wall of fibre-reinforced cementitious pseudo strain hardening (PSH) matrix. The matrix and a wall thickness to diameter ratio within a range are such that the pipe exhibits characteristic behaviour in diametral quasi-static bending under a 3-edge bearing method. The behaviour is such that a stress versus relative displacement curve for the pipe exhibits a substantially linear elastic region having a first slope within first limits, and from the LOP to the MOR for the pipe, a PSH region which, beyond a possible transition region, has a slope which is less than that of the elastic region and is within second limits.
Patent NZ-552074-A (NZ)
Title: Antidiabetic combination of metformin and one other antidiabetic agent such as a sulfonyl urea
Inventor: PIPER BETH ANNE
IPC: A61P1/00
Filed: 2000-10-13
Abstract: Disclosed is a use of metformin and at least one other antidiabetic agent, which is one or more of a sulfonyl urea (which may be selected from glyburide, glimepiride, glipyride, glipizide, chlorpropamide and gliclazide), for the preparation of a pharmaceutical formulation comprising a low dose combination of metformin and said at least one other antidiabetic agent, which provides at least substantially equivalent efficacy in treating diabetes in drug naive patients, but with substantially reduced side effects, as compared to metformin and said other antidiabetic agent employed in substantially higher daily dosages as prescribed in generally accepted medical practice for first line therapy in treating diabetes, for first line treatment of type 2 diabetes in a drug natve human patient, wherein the low dose combination includes metformin in an amount to provide a daily dosage within the range from about 160 mg to about 750 mg, in single or divided doses of one to four tablets daily, and wherein the ratio of metformin:sulfonyl urea is 250:1 to 150:1.
Patent NZ-552927-A (NZ)
Title: Preparation of alkyl-substituted 2-deoxy-2-fluoro-D-ribofuranosyl pyrimidines and purines and their derivatives
Inventor: WANG PEIYUAN
IPC: C07H1/00
Filed: 2005-07-21
Abstract: Disclosed is a compound according to Formula (I) wherein, the substituents are disclosed within the specification. The process for preparing the compound and intermediates used in the process are also disclosed. The compounds are alkyl-substituted 2-deoxy-2-fluro-D-ribofuranosyl pyrimidine and purine derivatives. The compound of Formula (I) is an anti-HCV inhibitor.
Patent NZ-553258-A (NZ)
Title: 5-[3-(4-Benzyloxyphenylthio)-fur-2-yl]-imidazolidin-2,4-dione and analogues as inhibitors of macrophage elastase
Inventor: YANG FUDE
IPC: A61K31/341
Filed: 2005-08-17
Abstract: Disclosed are hydantoin derivatives of formula (IV) (such as 5-[3-(4-benzyloxyphenylthio)furan-2-yl]imidazoline-2,4-dione) and their pharmaceutically acceptable salts, wherein R is selected from the group consisting of phenyl, 4-benzyloxyphenyl, 4-biphenyl, 4-methoxyphenyl, 3-methoxyphenyl, 2-methoxyphenyl, 3,5-dimethoxyphenyl, 4-chlorophenyl, 3-chlorophenyl, 2-chlorophenyl, 4-methylphenyl, 3-methylphenyl, 2-methylphenyl, and 3-trifluoromethylphenyl. Also disclosed is the use of a compound as defined above in the manufacture of a medicament to treat a disease or disorder responsive to inhibition of MMP-12 in a patient in need thereof (and particularly conditions such as asthma, chronic obstructive pulmonary disease (COPD), arthritis, cancer, heart disease or nephritis).
Patent NZ-554868-A (NZ)
Title: Use of THCV in manufacture of medicament for treating obesity, epilepsia, schizophrenia
Inventor: GUY GEOFFREY
IPC: A61K36/00
Filed: 2005-11-15
Abstract: Disclosed is the use of a therapeutically effective amount of tetrahydrocannabivarin (THCV) in the manufacture of a medicament for use in the treatment of diseases and conditions benefiting from neutral antagonism of the CB1 cannabinoid receptor, wherein the disease or condition to be treated is selected from the group consisting of: obesity; schizophrenia; epilepsy and obesity associated with type II diabetes (noninsulin dependant diabetes).
Patent NZ-554966-A (NZ)
Title: Isolated nucleic acids encoding APETALA2 (AP2) protein from a lolium species
Inventor: SPANGENBERG GERMAN
IPC: A01H5/00
Filed: 2001-10-17
Abstract: Disclosed is a substantially purified or isolated nucleic acid fragment encoding an APETALA2 (AP2) protein or a functionally active fragment or variant thereof from a Lolium species. The nucleic acid can be introduced into a plant to modify plant life cycles and/or growth phases, flowering processes, flowering and/or plant architecture and flower and/or inflorescence development in a plant, or can be used as a molecular marker.
Patent NZ-565255-A (NZ)
Title: Pyrrolo[2,3-b] pyridine derivatives as protein kinase inhibitors
Inventor: IBRAHIM PRAHBHA R
IPC: A61K31/435
Filed: 2006-06-21
Abstract: Disclosed are pyrrolo[2,3-b] pyridine derivatives of formula (IIIm) which are active on protein kinases, wherein the variables are as defined in the specification. These compounds are suitable to treat diseases and conditions associated with aberrant activity of protein kinases, wherein said disease or condition is selected from the group consisting of melanoma, glioma, thyroid cancer, liver cancer, lung cancer, colorectal cancer, prostate cancer, acute pain, chronic pain, and polycystic kidney disease.
Patent NZ-567319-A (NZ)
Title: Wood tracking by identification of surface characteristics
Inventor: FREEMAN PATRICK S
IPC: B27C1/00
Filed: 2004-07-23
Abstract: A wood tracking system is provided. The system includes at least two cameras for imaging multiple pieces of wood at least two different places as they travel through a production line, image processing software to adjust the images taken, image characterization software to characterise the wood surfaces of the wood in the images taken and comparison software to compare at least one characteristic value of the wood surface to determine whether images of the wood taken at the first and second points match.
Patent NZ-568372-A (NZ)
Title: Aqueous rodenticide formulations
Inventor: JAKOB JURGEN
IPC: A01M29/12
Filed: 2006-11-14
Abstract: Disclosed is a cereal grain treated with an aqueous rodenticide formulation and dried, the formulation comprising (a) at least one rodenticide (preferably a coumarin rodenticide such as flocumafen); (b) at least one polyol selected from the group consisting of glycol, polyethylene glycol, glycerol, propylene glycol and dipropylene glycol; (c) polyethylene wax or latex copolymer, based on styrene/butadiene; and (d) monosaccharide and/or disaccharide, where the content is 10.0 wt% to 50.0 wt%.
Patent NZ-570920-A (NZ)
Title: Pest repellent comprising geranylacetone and sulcatone
Inventor: PICKETT JOHN ANTHONY
IPC: A01N49/00
Filed: 2007-03-02
Abstract: Disclosed is the use of a composition comprising geranylacetone as an active ingredient plus a further active ingredient which is 6-methyl-5-hepten-2-one in the preparation of an inhibitory formulation for the treatment of a subject for inhibiting the activity of a haematophagous arthropod against the subject; wherein the haematophagous arthropod is an insect pest of the family Ceratopogonidae or family Culicidae or is a tick which may be selected from the list consisting of: members of the Culex pipiens complex; Aedes aegypti; Anopheles stephensi; Anopheles gambiae complex; Culicoides impunctatus; Culicoides molestus; Lutzomyia species; Phlebotomine species; Midges.
Patent NZ-572759-A (NZ)
Title: Pharmaceutical product for intraoral delivery of nicotine comprising trometamol as buffering agent
Inventor: STEEN PER
IPC: A61K9/00
Filed: 2007-04-18
Abstract: Disclosed is a buffered pharmaceutical oral formulation comprising nicotine that is buffered with trometamol. Also disclosed is the use of the oral formulation in the preparation of a medicament for reducing the urge to smoke or use of tobacco and/or for providing a sense of smoking satisfaction without smoking.
Patent NZ-575113-A (NZ)
Title: Method of optimizing the treatment of philadelphia-positive leukemia with abl tyrosine kinase inhibitors
Inventor: GATHMANN INSA
IPC: A61K49/00
Filed: 2007-09-20
Abstract: Provided is the use of Imatinib or a pharmaceutically acceptable salt thereof for the manufacture of a medicament for the treatment of a Ph+ leukemia in a patient, wherein (a) the patient has previously received a medicament adapted for oral administration of a predetermined fixed daily amount between 200 and 800 mg of the monomesylate salt of Imatinib, (b) at least one blood sample from the patient is analysed within the first 3 months of treatment, (c) the plasma trough level (Cmin) of Imatinib in the blood sample is determined, and (d) the dose of Imatinib or a pharmaceutically acceptable salt thereof is adjusted by choosing from a suitable pre-manufactured unit dosage in a manner that a Cmin between 1000 and 3000 ng/mL is achieved, wherein the patient does not reach a Cmin between 1000 and 3000 ng/mL of Imatinib after receiving the predetermined fixed amount of the monomesylate salt of Imatinib.
Patent NZ-575627-A (NZ)
Title: Polymorphic form of 4-[3-(4-cyclopropanecarbonyl-piperazine-1-carbonyl)-4-fluoro-benzyl]-2h-phthalazin-1-one
Inventor: MENEAR KEITH ALLAN
IPC: A61P35/00
Filed: 2007-10-15
Abstract: Disclosed herein is 4-[3-( 4-Cyclopropanecarbonyl-piperazine-1-carbonyl)-4-fluo ro-benzyl]-2 H-phthalazi n-1-one as crystalline form A having characteristic peaks in a powder XRD as defined within the specification, methods for its preparation, compositions comprising said compound and he use of the compound in the treatment of vascular disease; septic shock; ischaemic injury; neurotoxicity; haemorraghic shock; viral infection; or diseases ameliorated by the inhibition of the activity of PARP.
Patent NZ-576960-A (NZ)
Title: Foaming hard surface cleaner
Inventor: DIET PATRICK
IPC: C11D1/83
Filed: 2006-11-17
Abstract: Disclosed is a foamable composition comprising: a) at least one anionic surfactant that is a salt of an alkyl sulfate in an amount of 0.01 to 1 percent by weight of the composition, wherin the alkyl sulfate is a triethanolamine alkyl sulfate; b) at least one glycol ether in an amount of 0.1 to 1.5 percent by weight of the composition; c) at least one alcohol in an amount of about 2 to 6 percent by weight of the composition; and d) water.
Patent NZ-582489-A (NZ)
Title: A triple density replacement gel insole
Inventor: MARTINEZ JACOB
IPC: A43B13/41
Filed: 2008-09-11
Abstract: Disclosed is a triple density replacement insole, comprising: a generally foot-shaped substrate having a length extending from a heel area to an arch area to a toe area, a top surface and a bottom surface; at least two coextensive layers adjacent one another and extending the length of the insole, said coextensive layers comprising a first top cloth layer and a second gel layer, said gel layer having a first density; a stability cradle adjacent said gel layer and forming a portion of said bottom surface, said stability cradle, extending from the arch area to the heel area and secured to the gel layer, said stability cradle defining a first metatarsal region gap which exposes the gel layer and a second heel region gap which exposes the gel layer, said stability cradle having a second density; and a heel cushion forming a portion of said bottom surface, said heel cushion positioned in the second heel region gap adjacent to said gel layer and secured to said gel layer exposed in that region, said heel cushion having a third density,wherein said bottom surface preferably comprises a honeycomb pattern advanced cushioning area integrally formed in said gel layer and located in said toe area and positioned to lie generally below the ball of a user's foot.
Patent NZ-592751-A (NZ)
Title: Cellulolytic polypeptides and their use in micro-organisms for the production of solvents and fuels
Inventor: FIEROBE HENRI-PIERRE
IPC: C12N9/42
Filed: 2009-11-26
Abstract: Disclosed is a method for producing a solvent, fuel or chemical intermediate from a substance comprising cellulose, comprising: Expressing the ACLA polypeptide of Pseudomonas sp. ND137 represented in SEQ ID NO 1 or a homologue thereof having at least 70% sequence identity with SEQ ID NO 1, or a functional fragment of said ACLA polypeptide or of said homologue in a recombinant host micro-organism; and Contacting said substance with said ACLA polypeptide. Further disclosed is a recombinant micro-organism expressing said ACLA polypeptide, wherein said microorganism is capable of secreting said ACLA polypeptide or homologue thereof, and wherein said micro-organism is capable of degrading cellulose. Further disclosed is a mixture of enzymes comprising said ACLA protein and one or more cellulose-degrading enzymes from Clostridium cellulolyticum. Also disclosed is a solvent, fuel or chemical intermediate produced by said method.